ArticleFrontiers in molecular biosciences2019
Article in Frontiers in molecular biosciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 32 citations in OpenAlex.
- SORCS2 serves as a tumor suppressor and associates with immune infiltration in ovarian cancer.Journal of ovarian research · 2025Article
- Laminin α5: a key factor in tumor metastasis.Clinical & experimental metastasis · 2025Review
- Polymorphism in the Hsa-miR-4274 seed region influences the expression of PEX5 and enhances radiotherapy resistance in colorectal cancer.Frontiers of medicine · 2024Article
- Combined inhibition of histone deacetylase and cytidine deaminase improves epigenetic potency of decitabine in colorectal adenocarcinomas.Clinical epigenetics · 2023Article
- Editorial: Bioinformatics of genome regulation and systems biology, Volume III.Frontiers in genetics · 2023Article
- Deciphering the role of miR-187-3p/LRFN1 axis in modulating progression, aerobic glycolysis and immune microenvironment of clear cell renal cell carcinoma.Discover oncology · 2022Article
- A novel approach for a joint analysis of isomiR and mRNA expression data reveals features of isomiR targeting in breast cancer.Frontiers in genetics · 2022Article
- Article
- Pan-Cancer Analysis Reveals Common and Specific Relationships between Intragenic miRNAs and Their Host Genes.Biomedicines · 2021Article
- miRGTF-net: Integrative miRNA-gene-TF network analysis reveals key drivers of breast cancer recurrence.PloS one · 2021Article
- Hypoxia-Induced miR-148a Downregulation Contributes to Poor Survival in Colorectal Cancer.Frontiers in genetics · 2021Article
- Comprehensive Analysis of the Expression and Prognosis for Laminin Genes in Ovarian Cancer.Pathology oncology research : POR · 2021Article
- Editorial: Bioinformatics of Genome Regulation, Volume II.Frontiers in genetics · 2021Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 8 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Specificity of RNAi to selected target is challenged by off-target effects, both canonical and non-canonical. Notably, more than half of all human microRNAs are co-expressed with hosting them proteincoding genes. Here we dissect regulatory subnetwork centered on
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.